- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05142189
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)
LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: BioNTech clinical trials patient information
- Phone Number: +49 6131 9084
- Email: patients@biontech.de
Study Locations
-
-
-
Frankfurt, Germany, 60488
- Recruiting
- Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)
-
Hamburg, Germany, 20246
- Recruiting
- University Medical Center Hamburg-Eppendorf
-
Köln, Germany, 50937
- Recruiting
- Universitätsklinikum Köln
-
Mainz, Germany, 55131
- Recruiting
- Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR
-
-
-
-
-
Budapest, Hungary, 1122
- Recruiting
- National Institute of Oncology
-
Budapest, Hungary, 1077
- Recruiting
- ICON-PRA Budapest, Fázis 1 Vizsgálóhely
-
Budapest, Hungary, 1083
- Recruiting
- Semmelweis Egyetem ÁOK Belgyógyászati és Onkológiai Klinika
-
Gyongyos, Hungary, 3200
- Recruiting
- Clinexpert Ltd
-
-
-
-
-
Gdańsk, Poland, 80-214
- Recruiting
- Uniwersyteckie Centrum Kliniczne
-
Olsztyn, Poland, 10-357
- Recruiting
- Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie
-
Poznań, Poland, 60-693
- Recruiting
- NZOZ Medpolonia Sp. Z o.o
-
Warsaw, Poland, 02-781
- Recruiting
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
-
-
-
-
-
Badalona, Spain, 08916
- Recruiting
- Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain, 28033
- Recruiting
- MD Anderson Cancer Center
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Fundacion Jiménez Díaz
-
Madrid, Spain, 28050
- Recruiting
- START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC)
-
Santiago De Compostela, Spain, 15706
- Recruiting
- Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Hospital Clinico Universitario (University Clinical Hospital)
-
Sevilla, Spain, 41009
- Recruiting
- Hospital Universitario Virgen Macarena
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitario Y Politécnico La Fe
-
-
-
-
-
Ankara, Turkey, 06800
- Recruiting
- Ankara City Hospital
-
Ankara, Turkey, 06200
- Recruiting
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Istanbul, Turkey, 34718
- Recruiting
- Yeditepe University
-
Izmir, Turkey, 35100
- Recruiting
- Ege University School of Medicine Tulay Aktas Oncology Hospital
-
İzmir, Turkey, 35340
- Recruiting
- Dokuz Eylul Medical School
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Not yet recruiting
- Cambridge University Hospitals NHS Foundation Trust
-
Cardiff, United Kingdom, CF14 2TL
- Not yet recruiting
- Velindre NHS Trust
-
Liverpool, United Kingdom, L7 8YA
- Not yet recruiting
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
London, United Kingdom, W1T 7HA
- Recruiting
- University College London Hospitals NHS Foundation Trust
-
London, United Kingdom, SE1 9RT
- Not yet recruiting
- Guy's and St Thomas NHS Foundation Trust
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Not yet recruiting
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
-
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- NEXT Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
Patients must have histologically confirmed NSCLC and measurable disease by RECIST v1.1. Note: Patients in Cohort 1 and Cohort 5 do not have to present with measurable disease.
- Patients in Cohorts 1 to 4 must present with unresectable Stage III or metastatic Stage IV NSCLC by American Joint Commission on Cancer (AJCC) Cancer Staging Manual, Eighth Edition.
- Patients in Cohort 5 must present with unresectable Stage III NSCLC by AJCC Cancer Staging Manual, Eighth Edition before receiving pre-trial chemoradiotherapy.
- Patients in Cohort 6 with the initial diagnosis of resectable Stage II and Stage III NSCLC by AJCC Cancer Staging Manual, Eighth Edition.
- Patients in Cohorts 2, 4, 5, and 6 must be able to tolerate (additional) anti-PD-1 therapy (i.e., did not permanently discontinue anti-programmed death protein 1 [PD-1] / programmed death ligand 1 [PD-L1] therapy due to toxicity).
- Patients in Cohorts 2, 3, and 6 must have an Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1. Patients in Cohort 1, 4, and 5 with an ECOG-PS of 0-2 are eligible.
Cohort-specific inclusion criteria:
Cohort 1:
Patients' prior therapy must have included at least a PD-1/PD-L1 inhibitor and a platinum-based chemotherapy regimen as well as one other line of systemic therapy (except if a patient is not candidate for a platinum-based chemotherapy and/or PD-1/PD-L1 inhibitor and/or another line of systemic therapy).
- Note: Patients newly enrolled in Cohort 1B under clinical trial protocol v4.0 and subsequent versions of the clinical trial protocol must consent to mandatory blood sampling for peripheral blood mononuclear cells (PBMCs).
- Patients who are to start cemiplimab at Cycle 3 must present with PD-L1 expression of tumor proportion score (TPS) ≥1% in tumor cells (as determined locally).
Cohort 2:
- Patients must present with PD-L1 expression of tumor proportion score (TPS) ≥50% in tumor cells (as determined locally prior to inclusion in this trial).
Patients must present with progressive disease either
- in the advanced or metastasized stage of NSCLC: while on a PD-1/PD-L1 inhibitor therapy or within 6 months of termination of this treatment as first-line treatment. Or
- be refractory to ongoing adjuvant therapy with a PD-1/PD-L1 inhibitor that has been given for at least 3 months in monotherapy (i.e., after an initial combination therapy) before being enrolled into this trial.
Cohort 3:
- Patients' prior therapy must have included at least a PD-1/PD-L1 inhibitor and a platinum-based chemotherapy regimen (except if a patient is not candidate for a platinum-based chemotherapy and/or PD-1/PD-L1 inhibitor).
- Patients must present with progressive disease.
Cohort 4:
- Patients' who are not candidates for chemotherapy as first-line treatment for the advanced or metastasized stage of NSCLC may be enrolled if presenting with PD-L1 expression: TPS ≥1% in tumor cells (as determined locally).
Cohort 5:
- Patients' NSCLC must have been considered unresectable due to patients' condition and/or tumor-related factors and the patients must have undergone chemoradiotherapy before entering the trial.
Cohort 6:
- Patients' NSCLC must be considered technically and medically resectable.
- Patients must be considered eligible for neo-adjuvant treatment.
Key Exclusion Criteria:
- Ongoing active systemic treatment against NSCLC.
- Presence of a driver mutation for which approved target therapies are available except if the patient is not a candidate for the respective targeted therapy.
- Ongoing or recent evidence (within the last 5 years) of significant autoimmune disease that required treatment with systemic immunosuppressive treatments which may suggest risk for immune-related adverse events. Note: Patients with autoimmune-related hyperthyroidism, autoimmune-related hypothyroidism who are in remission, or on a stable dose of thyroid-replacement hormone, vitiligo, or psoriasis may be included.
- Current evidence of new or growing brain or spinal metastases during screening. Patients with leptomeningeal disease are excluded. Patients with known brain or spinal metastases may be eligible in Cohorts 1 to 4 if they:
- had radiotherapy or another appropriate therapy for the brain or spinal bone metastases, AND
- have no neurological symptoms that can be attributed to the current brain lesions, AND
- have stable brain or spinal disease on the computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent (confirmed by stable lesions on two scans at least 4 weeks apart), AND
- do not require steroid therapy for the treatment of brain or spinal metastases within 14 d before the first dose of trial treatment. Note: Spinal bone metastases (i.e., of the vertebrae) are allowed, unless imminent fracture or cord compression is anticipated.
- Systemic immune suppression:
Current use of chronic systemic steroid medication (≤5 mg/day prednisolone equivalent is allowed); patients using physiological replacement doses of prednisone for adrenal or pituitary insufficiency are eligible.
- Note: Steroid medication given for supportive or prophylactic reasons during CRT for patients in Cohort 5 needs to be tapered to ≤5 mg/day prednisolone equivalent at latest on the day before the trial treatment starts.
- Other clinically relevant systemic immune suppression within the last 3 months before trial enrollment.
- Known history of seropositivity for human immunodeficiency virus (HIV) with CD4+ T-cell (CD4+) counts <350 cells/µL and with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
- Prior splenectomy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 3 - BNT116 + docetaxel
|
intravenous infusion
intravenous injection
|
Experimental: Cohort 2 - BNT116 + cemiplimab (PD-1/PD-L1 inhibitor refractory/relapsed patients)
|
intravenous injection
intravenous infusion
|
Experimental: Cohort 4 - BNT116 + cemiplimab (frail patients)
|
intravenous injection
intravenous infusion
|
Experimental: Cohort 1A - BNT116 monotherapy
|
intravenous injection
|
Experimental: Cohort 1B - BNT116 monotherapy
|
intravenous injection
|
Experimental: Cohort 5 - BNT116 + cemiplimab (after concurrent chemoradiotherapy [CRT])
|
intravenous injection
intravenous infusion
|
Experimental: Cohort 6 - BNT116 + cemiplimab + carboplatin + paclitaxel
BNT116 + cemiplimab + carboplatin + paclitaxel as neo-adjuvant treatment followed by surgery, thereafter adjuvant treatment with BNT116 + cemiplimab
|
intravenous infusion
intravenous injection
intravenous infusion
intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cohorts 1, 2, 3, 4, and 6: Occurrence of dose-limiting toxicities (DLTs) during Cycle 1
Time Frame: assessed during the first cycle (21 days)
|
assessed during the first cycle (21 days)
|
Cohorts 1 to 6: Occurrence of treatment-emergent adverse events (TEAEs) reported by relationship, seriousness, and grade according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Time Frame: up to 27 months
|
up to 27 months
|
Cohort 6 only: Occurrence of post-surgical adverse events (AEs) related to BNT116 and cemiplimab
Time Frame: up to 27 months
|
up to 27 months
|
Cohort 6 only: Occurrence of treatment-related delays to surgery more than 9 weeks post the last dose of neo-adjuvant treatment
Time Frame: up to 6 months
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohorts 1 to 4: Overall response rate (ORR) defined as the number of patients with complete response (CR) or partial response (PR) as best overall response (BOR)
Time Frame: up to 27 months
|
according to response evaluation criteria in solid tumors (RECIST) v1.1 divided by the number of patients in the efficacy analysis set
|
up to 27 months
|
Cohorts 1 to 4: Duration of response (DoR) defined as the time from initial response until first objective tumor progression according to RECIST v1.1
Time Frame: up to 27 months
|
up to 27 months
|
|
Cohorts 1 to 4: Disease control rate (DCR) defined as the number of patients with CR or PR or stable disease (SD) as BOR according to RECIST v1.1 divided by the number of patients in the efficacy analysis set
Time Frame: up to 27 months
|
up to 27 months
|
|
Cohorts 1 to 4: Duration of disease control defined as the time from initial detection of stable disease or response until first objective tumor progression according to RECIST v1.1
Time Frame: up to 27 months
|
up to 27 months
|
|
Cohorts 1 to 4: Progression-free survival (PFS) defined as the time of first trial treatment until the first objective tumor progression according to RECIST v1.1 or death from any cause, whichever occurs first
Time Frame: up to 48 months
|
up to 48 months
|
|
All cohorts: Overall survival (OS) defined as the time of first trial treatment until death from any cause
Time Frame: up to 48 months
|
up to 48 months
|
|
Cohort 5 and 6: Event free survival (EFS) defined as the length of time from first trial treatment to any of the following events: progression of disease, recurrence of disease or death from any cause, whichever occurs first.
Time Frame: up to 48 months
|
up to 48 months
|
|
Cohort 5 and 6: EFS rate at 12 and 24 months defined as the number of patients without an EFS-defining event divided by the number of patients in the efficacy analysis set.
Time Frame: up to 24 months
|
up to 24 months
|
|
Cohort 6: Rate of pathologic responses defined as the number of patients with major or complete pathologic response in the surgical specimen from surgery after neo-adjuvant trial treatment divided by the number of patients in the efficacy analysis set.
Time Frame: At time of surgery (approximately after 3 months treatment)
|
At time of surgery (approximately after 3 months treatment)
|
|
Cohort 6: ORR at the end of neo-adjuvant treatment (using RECIST v1.1).
Time Frame: Up to 3 months
|
Up to 3 months
|
|
Cohort 6: Rate of progressive disease at the end of neo-adjuvant treatment (using RECIST v1.1).
Time Frame: Up to 3 months
|
Up to 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: BioNTech Responsible Person, BioNTech SE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Docetaxel
- Carboplatin
- Paclitaxel
- Cemiplimab
Other Study ID Numbers
- BNT116-01
- 2021-004739-94 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Paclitaxel
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium